EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tet Methylcytosine Dioxygenase 2 ( TET2 ) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension ( PAH ): Correlation With Altered Gene Expression Relevant to a Common T Cell Phenotype

Charles C T Hindmarch iD, François Potus, Ruaa Al-Qazazi, Benjamin P Ott, William C Nichols, Michael J Rauh, Stephen L Archer

Comprehensive Physiology · 2025

DOI: 10.1002/cph4.70011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comprehensive Physiology, 2025. Verfasst von Charles C T Hindmarch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Molecular Science (DBMS), Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: DNA Methylation, Proto-Oncogene Proteins, Pulmonary Arterial Hypertension, DNA-Binding Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, William J Henderson Foundation, Richard K. Start Memorial Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic changes in gene expression due to DNA methylation regulate pulmonary vascular structure and function. Genetic or acquired alterations in DNA methylation/demethylation can promote the development of pulmonary arterial hypertension (PAH). Here, we performed epigenome‐wide mapping of DNA methylation in whole blood from 10 healthy people and 19 age/sex‐matched PAH patients from the PAH Biobank. Exome sequencing confirmed the absence of known mutations in PAH‐associated gene variants identifying subjects with or without mutations of TET2, a putative PAH gene encoding the demethylating enzyme, TET2. DNA of patients with PAH and no TET2 mutation was hypermethylated compared to healthy controls. Patients with PAH and a TET2 mutation had greater DNA CpG methylation than mutation‐free PAH patients. Unique Differentially Methylated Regions (DMR) were more common in patients with PAH with TET2 mutations (1164) than in PAH without mutations (262). We correlated methylome findings with a public PAH transcriptomic RNA dataset, prioritizing targets that are both hypermethylated in our cohort and downregulated at the RNA level. Relative to controls, functional analysis reveals enriched functions related to T cell differentiation in PAH patients with a TET2 mutation. We identified genes with downregulated expression that were hypermethylated in PAH patients (with or without a TET2 mutation). In both cases, a conserved T cell phenotype emerged. Pan‐chromosomal hypermethylation in PAH is greatest in patients with TET2 mutations. Observed hypermethylation of genes involved in the pathogenesis of PAH, such as EIF2AK4, and transcription factors that regulate T cell development, such as TCF7, merit further study and may contribute to the inflammation in PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationProto-Oncogene ProteinsPulmonary Arterial HypertensionDNA-Binding ProteinsT-LymphocytesHumansDioxygenasesFemaleMaleMutationMiddle AgedAdultEpigenesis, GeneticAged

Stichwörter der Autor:innen

DNA methylationT cell differentiationepigeneticmetabolismreduced representation bisulfite sequencing (RRBS)transcription factor 7 (TCF7)

Substanzen

TET2 protein, humanDioxygenasesProto-Oncogene ProteinsDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Biomedical and Molecular Science (DBMS), Queen's University, Kingston, Ontario, Canada.
  • Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Queen's CardioPulmonary Unit, Translational Institute of Medicine (TIME), Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Pulmonary Hypertension Research Group, Center de Recherche de L'institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada.
  • Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.

ORCID-Profile: Charles C T Hindmarch

Förderung

  • CIHR
  • William J Henderson Foundation
  • Richard K. Start Memorial Fund
  • NIH HHS
  • Canada Foundation for Innovation
  • William M. Spear Endowment Fund in Pulmonary Research
  • NHLBI NIH HHS
  • Canadian Institutes of Health Research

Zitieren

APA

Hindmarch, C. C. T., Potus, F., Al-Qazazi, R., Ott, B. P., Nichols, W. C., Rauh, M. J., & Archer, S. L. (2025). Tet Methylcytosine Dioxygenase 2 ( TET2 ) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension ( PAH ): Correlation With Altered Gene Expression Relevant to a Common T Cell Phenotype. Comprehensive Physiology. https://doi.org/10.1002/cph4.70011

Vancouver

Hindmarch CCT, Potus F, Al-Qazazi R, Ott BP, Nichols WC, Rauh MJ, et al. Tet Methylcytosine Dioxygenase 2 ( TET2 ) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension ( PAH ): Correlation With Altered Gene Expression Relevant to a Common T Cell Phenotype. Comprehensive Physiology. 2025. doi:10.1002/cph4.70011

BibTeX
@article{Hindmarch2025,
  author = {Hindmarch, Charles C T and Potus, François and Al-Qazazi, Ruaa and Ott, Benjamin P and Nichols, William C and Rauh, Michael J and Archer, Stephen L},
  title = {Tet Methylcytosine Dioxygenase 2 ( TET2 ) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension ( PAH ): Correlation With Altered Gene Expression Relevant to a Common T Cell Phenotype},
  journal = {Comprehensive Physiology},
  year = {2025},
  doi = {10.1002/cph4.70011}
}
Kostenlos starten →